1. Home
  2. BFS vs SGMT Comparison

BFS vs SGMT Comparison

Compare BFS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saul Centers Inc.

BFS

Saul Centers Inc.

N/A

Current Price

$28.57

Market Cap

902.2M

Sector

Real Estate

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$9.85

Market Cap

761.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BFS
SGMT
Founded
1993
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
902.2M
761.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
BFS
SGMT
Price
$28.57
$9.85
Analyst Decision
Strong Buy
Buy
Analyst Count
2
12
Target Price
★ $43.00
$27.91
AVG Volume (30 Days)
121.8K
★ 1.2M
Earning Date
11-05-2026
11-20-2026
Dividend Yield
★ 8.19%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.78
N/A
Revenue
★ $289,843,000.00
$2,000,000.00
Revenue This Year
$7.44
N/A
Revenue Next Year
$3.40
N/A
P/E Ratio
$58.20
★ N/A
Revenue Growth
★ 7.81
N/A
52 Week Low
$28.56
$4.50
52 Week High
$38.42
$11.45

Technical Indicators

Market Signals
Indicator
BFS
SGMT
Relative Strength Index (RSI) 39.14 50.81
Support Level $28.56 $6.44
Resistance Level $35.04 $11.23
Average True Range (ATR) 0.65 0.65
MACD 0.03 0.01
Stochastic Oscillator 22.93 42.11

Price Performance

Historical Comparison
BFS
SGMT

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: